NO2699580T3 - - Google Patents
Info
- Publication number
- NO2699580T3 NO2699580T3 NO12774761A NO12774761A NO2699580T3 NO 2699580 T3 NO2699580 T3 NO 2699580T3 NO 12774761 A NO12774761 A NO 12774761A NO 12774761 A NO12774761 A NO 12774761A NO 2699580 T3 NO2699580 T3 NO 2699580T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461931090P | 2014-01-24 | 2014-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2699580T3 true NO2699580T3 (de) | 2018-02-24 |
Family
ID=52432834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO12774761A NO2699580T3 (de) | 2014-01-24 | 2012-04-15 |
Country Status (37)
Country | Link |
---|---|
US (18) | US9522894B2 (de) |
EP (3) | EP3744714A1 (de) |
JP (5) | JP6469711B2 (de) |
KR (1) | KR102417684B1 (de) |
CN (2) | CN110483492B (de) |
AP (1) | AP2016009322A0 (de) |
AR (1) | AR099177A1 (de) |
AU (4) | AU2015208932C1 (de) |
BR (1) | BR112016016224B1 (de) |
CA (1) | CA2935625C (de) |
CL (1) | CL2016001889A1 (de) |
CR (1) | CR20160327A (de) |
CY (2) | CY1120049T1 (de) |
DK (2) | DK3097086T3 (de) |
DO (1) | DOP2016000175A (de) |
EA (1) | EA032794B1 (de) |
ES (2) | ES2658516T3 (de) |
HK (2) | HK1225730B (de) |
HR (2) | HRP20180116T1 (de) |
HU (2) | HUE038274T2 (de) |
IL (3) | IL246614B (de) |
LT (2) | LT3097086T (de) |
MX (1) | MX368840B (de) |
MY (1) | MY194850A (de) |
NO (1) | NO2699580T3 (de) |
NZ (2) | NZ722063A (de) |
PE (1) | PE20161218A1 (de) |
PH (1) | PH12016501439B1 (de) |
PL (2) | PL3323814T3 (de) |
PT (2) | PT3323814T (de) |
RS (2) | RS60639B1 (de) |
SG (2) | SG11201606052TA (de) |
SI (2) | SI3323814T1 (de) |
TW (1) | TWI690517B (de) |
UY (1) | UY35963A (de) |
WO (1) | WO2015110826A1 (de) |
ZA (2) | ZA201605856B (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2699580T3 (de) | 2014-01-24 | 2018-02-24 | ||
KR20190035781A (ko) * | 2016-07-29 | 2019-04-03 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
CA3089240A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
CA3091707A1 (en) | 2018-03-01 | 2019-09-06 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
US11998553B2 (en) | 2018-07-17 | 2024-06-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
CA3106270A1 (en) * | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
CN111689923B (zh) * | 2019-03-12 | 2022-11-08 | 中国科学院上海药物研究所 | 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途 |
CA3150236A1 (en) * | 2019-10-23 | 2021-04-29 | Young Il Choi | COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHIES (COPD) |
AU2021314104A1 (en) * | 2020-07-20 | 2023-01-19 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
EP4129989B1 (de) * | 2020-08-26 | 2024-10-02 | Haisco Pharmaceuticals Pte. Ltd. | Nitrilderivat als dipeptidylpeptidase-1-hemmer und verwendung davon |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN114159446A (zh) * | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
WO2022117059A1 (zh) | 2020-12-04 | 2022-06-09 | 瑞石生物医药有限公司 | 组织蛋白酶c小分子抑制剂及其医药用途 |
WO2022140516A1 (en) * | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
EP4289827A1 (de) * | 2021-02-05 | 2023-12-13 | Medshine Discovery Inc. | 1,4-oxazepane enthaltende kondensierte ringderivate |
CA3236069A1 (en) * | 2021-10-29 | 2023-05-04 | Ariel Teper | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
WO2023134656A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海壹典医药科技开发有限公司 | 一种肽基腈类化合物及其应用 |
IL314769A (en) * | 2022-02-16 | 2024-10-01 | Insmed Incorporated | Seratin N-(1-cyano-2-phenylethyl)-4,1-oxazapan-2-carboxamides for the treatment of hidradenitis suppurativa |
IL314855A (en) * | 2022-02-22 | 2024-10-01 | Haisco Pharmaceuticals Pte Ltd | Preparation method of a heterocyclic compound containing nitrogen |
CN118660873A (zh) * | 2022-02-22 | 2024-09-17 | 西藏海思科制药有限公司 | 二肽基肽酶抑制剂化合物的盐及晶型 |
WO2023160579A1 (zh) * | 2022-02-22 | 2023-08-31 | 四川海思科制药有限公司 | 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途 |
CN114644562B (zh) * | 2022-04-29 | 2023-08-22 | 常州大学 | 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用 |
TW202404961A (zh) * | 2022-06-07 | 2024-02-01 | 大陸商瑞石生物醫藥有限公司 | 苯并[c]色滿化合物的可藥用鹽、其多晶型及用途 |
WO2023236879A1 (zh) * | 2022-06-07 | 2023-12-14 | 瑞石生物医药有限公司 | 苯并[c]色满化合物的多晶型及其制备方法和用途 |
WO2024008680A1 (en) | 2022-07-06 | 2024-01-11 | Chiesi Farmaceutici S.P.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
WO2024081889A1 (en) | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
WO2024148308A1 (en) * | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
WO2024193695A1 (zh) * | 2023-03-23 | 2024-09-26 | 西藏海思科制药有限公司 | 一种二肽基肽酶小分子抑制剂的药物组合物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2782151B2 (ja) | 1993-07-16 | 1998-07-30 | 博 吉田 | 衝撃吸収柵用の端ストッパ |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
WO2002020804A1 (en) | 2000-09-08 | 2002-03-14 | Prozymex A/S | Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses |
EP1217000A1 (de) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Faktor Xa und Faktor VIIa Inhibitoren |
CN1315806C (zh) | 2001-12-04 | 2007-05-16 | 霍夫曼·拉罗奇有限公司 | 取代的2-氨基-环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途 |
US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
EP2258365B1 (de) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Verwendung von organischen verbindungen zur immunstärkung |
US20070155803A1 (en) | 2003-05-30 | 2007-07-05 | Prozymex A/S | Protease inhibitors |
JP2006527704A (ja) * | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
PT1732949E (pt) | 2004-04-07 | 2010-03-23 | Univ Minnesota | Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso |
EP1745292A2 (de) | 2004-04-28 | 2007-01-24 | Bayer HealthCare AG | Diagnositka und therapeutika für mit dipeptidyl-peptidase 1 (dpp1) assoziierten krankheiten |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
EP1916994B1 (de) | 2004-06-29 | 2013-12-11 | Takeda Pharma A/S | Herstellung einer pharmazeutischen zusammensetzung mit schneller freisetzung aus wasserunlöslichen arzneimitteln und mit dem erfindungsgemässen verfahren erhaltene pharmazeutische zusammensetzungen |
WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
EP1853250B1 (de) | 2005-02-18 | 2011-11-02 | Abraxis BioScience, LLC | Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie |
JP2009500347A (ja) | 2005-06-30 | 2009-01-08 | アムジエン・インコーポレーテツド | ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 |
CA2680312A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
CN101873851A (zh) | 2007-09-25 | 2010-10-27 | 诺瓦提斯公司 | 用气雾化药物如万古霉素治疗肺部疾病 |
WO2009074829A1 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
UY31867A (es) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
MX2011006108A (es) | 2008-12-08 | 2011-11-18 | Vm Pharma Llc | Composiciones de inhibidores de los receptores tirosina quinasa. |
WO2010114405A2 (en) | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
BRPI1015540A2 (pt) * | 2009-05-07 | 2019-09-24 | Astrazeneca Ab | ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750'' |
WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
CN106943403A (zh) | 2010-04-07 | 2017-07-14 | 弗特克斯药品有限公司 | 药物组合物和其给药方法 |
WO2011154677A1 (en) * | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
IT1404036B1 (it) | 2010-12-17 | 2013-11-08 | Oto Melara Spa | Veicolo armato con struttura migliorata. |
SG192669A1 (en) | 2011-02-11 | 2013-09-30 | Glaxosmithkline Ip Dev Ltd | Cathepsin c inhibitors |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
AU2013224421B2 (en) | 2012-02-21 | 2017-03-02 | Merck Patent Gmbh | 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors |
CN104284895B (zh) | 2012-04-17 | 2016-08-31 | 安斯泰来制药株式会社 | 含氮双环式芳香族杂环化合物 |
WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
EP2775304A1 (de) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Verfahren zum Nachweis einer entzündlichen Störung |
EP2970228B1 (de) | 2013-03-14 | 2017-05-10 | Boehringer Ingelheim International GmbH | Substituierte 2-aza-bicyclo[2.2.1]heptan-3-carboxylsäure (cyan-methyl)-amid-hemmstoffen von cathepsin c |
US8889708B2 (en) | 2013-03-14 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
WO2014140091A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
DK2970283T3 (da) | 2013-03-14 | 2021-01-25 | Boehringer Ingelheim Int | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c |
UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
US10670594B2 (en) | 2013-08-22 | 2020-06-02 | Emory University | Devices and methods related to airway inflammation |
WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
AU2014317048B2 (en) | 2013-09-09 | 2018-05-10 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
NO2699580T3 (de) | 2014-01-24 | 2018-02-24 | ||
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
TW201622721A (zh) | 2014-04-10 | 2016-07-01 | 諾華公司 | S1p調節劑之立即釋放劑量療法 |
EP3466432B1 (de) | 2014-05-15 | 2020-07-08 | Insmed Incorporated | Verfahren zur behandlung von pulmonaler mykobakterieller nichttuberkuloseinfektionen |
EP3149192B1 (de) | 2014-05-30 | 2019-01-02 | Versitech Limited | Verfahren und zusammensetzungen zur verwendung von neutrophiler elastase und proteinase 3 als diagnostische biomarker |
WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
SI3191487T1 (sl) | 2014-09-12 | 2019-12-31 | Boehringer Ingelheim International Gmbh | Spirociklični inhibitorji katepsina C |
EP3218372B1 (de) | 2014-11-14 | 2020-05-20 | Boehringer Ingelheim International GmbH | Morpholin- und 1,4-oxazepanamide als somatostatinrezeptor-subtyp-4(sstr4)-agonisten |
US10479781B2 (en) | 2015-03-05 | 2019-11-19 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
KR20190035781A (ko) | 2016-07-29 | 2019-04-03 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
CA3089240A1 (en) | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
CA3091707A1 (en) | 2018-03-01 | 2019-09-06 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
US11998553B2 (en) | 2018-07-17 | 2024-06-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
CA3106270A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
KR20220022115A (ko) | 2019-04-17 | 2022-02-24 | 아조라 테라퓨틱스 인코포레이티드 | 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법 |
MX2021014742A (es) | 2019-06-05 | 2022-02-11 | Univ Emory | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. |
WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
KR20240004691A (ko) | 2021-04-29 | 2024-01-11 | 인스메드 인코포레이티드 | 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드 |
WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
CA3236069A1 (en) | 2021-10-29 | 2023-05-04 | Ariel Teper | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
IL314769A (en) | 2022-02-16 | 2024-10-01 | Insmed Incorporated | Seratin N-(1-cyano-2-phenylethyl)-4,1-oxazapan-2-carboxamides for the treatment of hidradenitis suppurativa |
-
2012
- 2012-04-15 NO NO12774761A patent/NO2699580T3/no unknown
-
2015
- 2015-01-21 US US14/601,371 patent/US9522894B2/en active Active
- 2015-01-23 PL PL17195612T patent/PL3323814T3/pl unknown
- 2015-01-23 JP JP2016548068A patent/JP6469711B2/ja active Active
- 2015-01-23 DK DK15701577.7T patent/DK3097086T3/en active
- 2015-01-23 HU HUE15701577A patent/HUE038274T2/hu unknown
- 2015-01-23 EP EP20173862.2A patent/EP3744714A1/de active Pending
- 2015-01-23 CN CN201910716882.4A patent/CN110483492B/zh active Active
- 2015-01-23 UY UY0001035963A patent/UY35963A/es not_active Application Discontinuation
- 2015-01-23 DK DK17195612.1T patent/DK3323814T3/da active
- 2015-01-23 EP EP15701577.7A patent/EP3097086B1/de active Active
- 2015-01-23 RS RS20200858A patent/RS60639B1/sr unknown
- 2015-01-23 SI SI201531287T patent/SI3323814T1/sl unknown
- 2015-01-23 PE PE2016001236A patent/PE20161218A1/es unknown
- 2015-01-23 BR BR112016016224-2A patent/BR112016016224B1/pt active IP Right Grant
- 2015-01-23 TW TW104102345A patent/TWI690517B/zh active
- 2015-01-23 PT PT171956121T patent/PT3323814T/pt unknown
- 2015-01-23 NZ NZ722063A patent/NZ722063A/en unknown
- 2015-01-23 NZ NZ734768A patent/NZ734768A/en unknown
- 2015-01-23 MY MYPI2016702657A patent/MY194850A/en unknown
- 2015-01-23 SG SG11201606052TA patent/SG11201606052TA/en unknown
- 2015-01-23 AR ARP150100202A patent/AR099177A1/es active IP Right Grant
- 2015-01-23 AU AU2015208932A patent/AU2015208932C1/en active Active
- 2015-01-23 KR KR1020167022665A patent/KR102417684B1/ko active IP Right Grant
- 2015-01-23 CN CN201580005484.1A patent/CN105980367B/zh active Active
- 2015-01-23 RS RS20180069A patent/RS56919B1/sr unknown
- 2015-01-23 LT LTEP15701577.7T patent/LT3097086T/lt unknown
- 2015-01-23 EA EA201691375A patent/EA032794B1/ru unknown
- 2015-01-23 LT LTEP17195612.1T patent/LT3323814T/lt unknown
- 2015-01-23 AP AP2016009322A patent/AP2016009322A0/en unknown
- 2015-01-23 ES ES15701577.7T patent/ES2658516T3/es active Active
- 2015-01-23 HU HUE17195612A patent/HUE052421T2/hu unknown
- 2015-01-23 PT PT157015777T patent/PT3097086T/pt unknown
- 2015-01-23 SI SI201530170T patent/SI3097086T1/en unknown
- 2015-01-23 PL PL15701577T patent/PL3097086T3/pl unknown
- 2015-01-23 EP EP17195612.1A patent/EP3323814B1/de active Active
- 2015-01-23 SG SG10201701056QA patent/SG10201701056QA/en unknown
- 2015-01-23 CR CR20160327A patent/CR20160327A/es unknown
- 2015-01-23 MX MX2016009349A patent/MX368840B/es active IP Right Grant
- 2015-01-23 WO PCT/GB2015/050155 patent/WO2015110826A1/en active Application Filing
- 2015-01-23 CA CA2935625A patent/CA2935625C/en active Active
- 2015-01-23 ES ES17195612T patent/ES2808060T3/es active Active
-
2016
- 2016-07-05 IL IL246614A patent/IL246614B/en active IP Right Grant
- 2016-07-13 DO DO2016000175A patent/DOP2016000175A/es unknown
- 2016-07-20 PH PH12016501439A patent/PH12016501439B1/en unknown
- 2016-07-25 CL CL2016001889A patent/CL2016001889A1/es unknown
- 2016-08-23 ZA ZA2016/05856A patent/ZA201605856B/en unknown
- 2016-11-08 US US15/346,411 patent/US9815805B2/en active Active
- 2016-12-12 HK HK16114117A patent/HK1225730B/zh unknown
-
2017
- 2017-01-18 AU AU2017200338A patent/AU2017200338B2/en active Active
- 2017-06-11 IL IL252836A patent/IL252836A0/en active IP Right Grant
- 2017-09-19 US US15/708,634 patent/US10287258B2/en active Active
-
2018
- 2018-01-22 HR HRP20180116TT patent/HRP20180116T1/hr unknown
- 2018-01-22 ZA ZA2018/00431A patent/ZA201800431B/en unknown
- 2018-02-05 CY CY20181100132T patent/CY1120049T1/el unknown
- 2018-04-30 AU AU2018202956A patent/AU2018202956B2/en active Active
- 2018-11-22 HK HK18114946.6A patent/HK1255870A1/zh unknown
-
2019
- 2019-01-16 JP JP2019005300A patent/JP6804570B2/ja active Active
- 2019-03-19 US US16/358,091 patent/US10669245B2/en active Active
- 2019-03-25 IL IL265611A patent/IL265611A/en unknown
- 2019-04-17 AU AU2019202675A patent/AU2019202675B2/en active Active
-
2020
- 2020-04-22 US US16/855,522 patent/US11117874B2/en active Active
- 2020-07-23 HR HRP20201147TT patent/HRP20201147T1/hr unknown
- 2020-07-23 CY CY20201100674T patent/CY1123391T1/el unknown
- 2020-12-02 JP JP2020200413A patent/JP7157791B2/ja active Active
-
2021
- 2021-02-08 US US17/170,641 patent/US11667615B2/en active Active
-
2022
- 2022-04-04 JP JP2022062548A patent/JP7336563B2/ja active Active
- 2022-09-09 US US17/942,111 patent/US11773069B2/en active Active
- 2022-09-09 US US17/942,106 patent/US11655221B2/en active Active
- 2022-09-10 US US17/942,122 patent/US11655224B2/en active Active
- 2022-09-10 US US17/942,112 patent/US11673871B2/en active Active
- 2022-09-10 US US17/942,121 patent/US11655223B2/en active Active
- 2022-09-10 US US17/942,123 patent/US11814359B2/en active Active
- 2022-09-10 US US17/942,120 patent/US11655222B2/en active Active
- 2022-09-15 US US17/946,024 patent/US11680049B2/en active Active
- 2022-09-16 US US17/946,112 patent/US11673872B2/en active Active
-
2023
- 2023-04-13 US US18/300,350 patent/US20230250071A1/en not_active Abandoned
- 2023-08-21 JP JP2023133935A patent/JP2023156479A/ja active Pending
- 2023-12-08 US US18/533,894 patent/US12054465B2/en active Active
-
2024
- 2024-06-17 US US18/745,710 patent/US20240336582A1/en active Pending